Mutations in genes such as TP53, PIK3CA, BRCA1, and BRCA2 can be identified in EV DNA from breast cancer patients, and breastcancers caused by mutations in BRCA1 and TP53 may be targeted through strategies aimed at reactivatingmutant p53. This evidence concerns the gene BRCA1 and breast carcinoma.